Ascletis Pharma (HKG:1672) said it completed patient enrollment in the phase 2 study of its oral drug ASC30 in the U.S., according to a Hong Kong bourse filing Monday.
The firm will study the drug as a treatment for type 2 diabetes over a 13-week period. Topline data from the investigation is expected in the third quarter of 2026, according to Ascletis.
ASC30 is also being developed as a treatment for obesity.
Chifeng Jilong Gold Mining (SHA:600988, HKG:6693) recorded a 104% rise in attributable profit in the first quarter of 2025 to 988.2 million yuan from 483.4 million yuan in the year-ago period, according to a Friday Hong Kong bourse filing.The miner's earnings per share jumped to 0.52 yuan from 0.29 yuan in the corresponding period of the previous fiscal year.Operating income increased 48% to 3.55 billion yuan from 2.41 billion yuan a year prior.The firm attributed the positive performance to the optimization of production organization and operational management, allowing the firm to benefit from a year-over-year rise in goldselling price.
Jiayuan Services (HKG:1153) completed the placing of 60.5 million shares to two investors at HK$0.25 apiece to raise net proceeds of HK$14.6 million, according to a Friday Hong Kong bourse filing.The shares represent approximately 9% of the real estate developer's enlarged issued share capital.The firm will use proceeds for general working capital, as well as for the settlement of outstanding payables.
BOCOM International (HKG:3329) unit Preferred Investment Management acquired $9 million of certain bonds for $9.1 million from the over-the-counter market on Wednesday, according to a Friday Hong Kong bourse filing.The bonds will be issued by Sumitomo Mitsui Trust Bank and listed on the Singapore Exchange.The company purchased the bonds for investment purposes.